ALKEM LABORATORIES LTD.
NSE : ALKEMBSE : 539523ISIN
CODE : INE540L01014Industry : Pharmaceuticals & DrugsHouse
: Private
BSE5438.80-1.45 (-0.03 % )
PREV CLOSE (Rs.) 5440.25
OPEN PRICE (Rs.) 5440.25
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 845
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE5438.25 0.55 (+0.01 % )
PREV CLOSE(Rs.) 5437.70
OPEN PRICE (Rs.) 5485.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 12829
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 28-Mar-2024 | Alkem Laboratories incorporates wholly owned subsidiary | <p style="text-align: justify;">Alkem Laboratories has incorporated Wholly Owned Subsidiary (WOS) of the Company in the name of ‘Alkem Medtech'. The company has incorporated WOS on March 27, 2024 in India. Alkem Medtech has been incorporated for exploring the medical device segment mainly in the cardiovascular and orthopedic fields.</p><p style="text-align: justify;">Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.</p> |
| 28-Mar-2024 | USFDA concludes inspection at Alkem Laboratories' manufacturing facility at Baddi | <p style="text-align: justify;">U.S Food and Drug Administration (USFDA) has concluded inspection at Alkem Laboratories' manufacturing facility located at Baddi, India. The said inspection conducted from March 19, 2024 to March 27, 2024. </p><p style="text-align: justify;">At the end of the inspection, the company has received Form 483 with ten observations. This was a GMP as well as a Pre-Approval Inspection. There is no data integrity observation.</p><p style="text-align: justify;">Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.</p><div style="text-align: justify;"><br></div> |
| 06-Mar-2024 | Alkem Laboratories informs about notice of postal ballot | <div>Alkem Laboratories has informed that it attached the Postal Ballot Notice dated 09th February, 2024 for the business as specified in the notice. </div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 28-Feb-2024 | USFDA issues EIR for Alkem Laboratories' API manufacturing facility at Mandva | <p style="text-align: justify;">U.S Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Alkem Laboratories' API manufacturing facility located at Mandva, Maharashtra. The inspection has been classified as Voluntary Action Indicated (VAI) and was closed accordingly.</p><p style="text-align: justify;">Earlier, USFDA had concluded inspection at the company's API manufacturing facility located at Mandva, Maharashtra. The said inspection conducted from November 27, 2023 to December 01, 2023. At the end of the inspection, the company has received Form 483 with three observations. </p><p style="text-align: justify;">Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.</p><div style="text-align: justify;"><br></div> |
| 28-Feb-2024 | Alkem Laboratories informs about press release | <div style="text-align: justify;">In furtherance to the intimation captioned ‘US FDA Inspection at Company's API manufacturing facility located at Mandva' dated 01st December, 2023, Alkem Laboratories has informed that US FDA has issued an Establishment Inspection Report (EIR) for the said manufacturing facility. The Inspection has been classified as Voluntary Action Indicated (VAI) and was closed accordingly.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 27-Feb-2024 | Clarification sought from Alkem Laboratories Ltd | The Exchange has sought clarification from Alkem Laboratories Ltd on February 27, 2024, with reference to Movement in Volume. The reply is awaited. |
| 27-Feb-2024 | Alkem Laboratories informs about clarification | <div>Alkem Laboratories has informed that the Company is in compliance with the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Listing Regulations) and has been promptly intimating the Stock Exchanges regarding all events/ information which may have a bearing on the operation/ performance of the Company. There is no undisclosed price sensitive information which needs to be informed to the exchange at this point of time. Further, informed that Company will, as required under the Listing Regulations continue to promptly intimate the stock exchanges of all material events / information / actions. </div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div><div><br></div> |
| 26-Feb-2024 | Alkem Laboratories informs about clarification media statement | <p style="text-align: justify;">Alkem Laboratories has informed that it enclosed the clarification letter with respect to news articles published by the press/ media.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p><div style="text-align: justify;"><br></div> |
| 16-Feb-2024 | Alkem Laboratories informs about disclosure | <p style="text-align: justify;">Alkem Laboratories has informed that the exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Madhurima Singh & Others.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 14-Feb-2024 | Alkem Laboratories informs about transcript of conference call | <p style="text-align: justify;">Alkem Laboratories has informed that it enclosed the transcript of the ‘Q3 FY2024 Earnings Conference Call' which was hosted by the Company on Friday, 09th February, 2024. The said transcript shall also be made available on the website of the Company.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p><div style="text-align: justify;"><br></div> |
